Pharmacokinetics and anti-inflammatory pharmacodynamics of prednisolone in cynomolgus monkey

References

• Almawi WY, Melemedjian OK. 2002. Molecular mechanisms of glucocorticoid antiproliferative effects: antagonism of transcription factor activity by glucocorticoid receptor. J Leukoc Biol 71:9–15.
   PubMed Web of Science ®Google Scholar
• Banker MJ, Clark TH, Williams JA. 2003. Development and validation of a 96-well equilibrium dialysis apparatus for measuring plasma protein binding. J Pharm Sci 92:967–74.
   PubMed Web of Science ®Google Scholar
• Barth J, Damoiseaux M, Mollmann H, Brandis KH, Hochhaus G, Derendorf H. 1992. Pharmacokinetics and pharmacodynamics of prednisolone after intravenous and oral administration. Int J Clin Pharmacol Ther Toxicol 30:317–24.
   PubMed Web of Science ®Google Scholar
• Boudinot FD, Jusko WJ. 1986. Dose-dependent pharmacokinetics of prednisolone in normal and adrenalectomized rats. J Pharmacokinet Biopharm 14:453–67.
   PubMedGoogle Scholar
• Chakraborty A, Yeung S, Pyszczynski NA, Jusko WJ. 2005. Pharmacodynamic interactions between recombinant mouse interleukin-10 and prednisolone using a mouse endotoxemia model. J Pharm Sci 94:590–603.
   PubMedGoogle Scholar
• Coe CL, Kramer M, Kirschbaum C, Netter P, Fuchs E. 2002. Prenatal stress diminishes the cytokine response of leukocytes to endotoxin stimulation in juvenile rhesus monkeys. J Clin Endocrinol Metab 87:675–81.
   PubMed Web of Science ®Google Scholar
• Czock D, Keller F, Rasche FM, Haussler U. 2005. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet 44:61–98.
   PubMed Web of Science ®Google Scholar
• Dayneka NL, Garg V, Jusko WJ. 1993. Comparison of four basic models of indirect pharmacodynamic response. J Pharmacokinet Biopharm 21:457–78.
   PubMedGoogle Scholar
• de Kruif MD, Lemaire LC, Giebelen IA, Van Zoelen MA, Pater JM, Van den Pangaart PS, Groot AP, de Vos AF, Elliott PJ, Meijers JC, Levi M, Van der Poll T. 2007. Prednisolone dose-dependently influences inflammation and coagulation during human endotoxemia. J Immunol 178:1845–51.
   PubMedGoogle Scholar
• El Dareer SM, Struck RF, White VM, Mellett LB, Hill DL. 1977. Distribution and metabolism of prednisone in mice, dogs, and monkeys. Cancer Treat Rep 61:1279–89.
   PubMedGoogle Scholar
• Feldmann M. 1996. The cytokine network in rheumatoid arthritis: definition of TNF alpha as a therapeutic target. J R Coll Physicians Lond 30:560–70.
   PubMedGoogle Scholar
• Frey BM, Frey FJ. 1990. Clinical pharmacokinetics of prednisone and prednisolone. Clin Pharmacokinet 19:126–46.
   PubMed Web of Science ®Google Scholar
• Frey FJ, Frey BM, Greither A, Benet LZ. 1980. Prednisolone clearance at steady state in dogs. J Pharmacol Exp Ther 215:287–91.
   PubMedGoogle Scholar
• Frey FJ, Frey BM. 1982. Inequality of clearance values obtained by intravenous bolus and by steady-state infusion. Prednisolone studies in dogs. Pharmacology 24:346–54.
   PubMedGoogle Scholar
• Garrelds IM, Van Hal PT, Haakmat RC, Hoogsteden HC, Saxena PR, Zijlstra FJ. 1999. Time dependent production of cytokines and eicosanoids by human monocytic leukaemia U937 cells; effects of glucocorticosteroids. Mediators Inflamm 8:229–35.
   PubMedGoogle Scholar
• Hammarlund-Udenaes M, Benet LZ. 1991. Prednisone and prednisolone interconversion in the rabbit utilizing unbound concentrations. Biopharm Drug Dispos 12:467–77.
   PubMedGoogle Scholar
• Huang ML, Jusko WJ. 1990. Non-linear pharmacokinetics and interconversion of prednisolone and prednisone in rats. J Pharmacokinet Biopharm 18:401–21.
   PubMedGoogle Scholar
• Jusko WJ, Rose JQ. 1980. Monitoring prednisone and prednisolone. Ther Drug Monit 2:169–76.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A. 2002. Combination cytokine therapy: the next generation of rheumatoid arthritis therapy? Arthritis Rheum 47:87–92.
   PubMedGoogle Scholar
• Kong AN, Jusko WJ. 1991. Disposition of methylprednisolone and its sodium succinate prodrug in vivo and in perfused liver of rats: non-linear and sequential first-pass elimination. J Pharm Sci 80:409–15.
   PubMedGoogle Scholar
• Lewis GP, Jusko WJ, Graves L, Burke CW. 1971. Prednisone side-effects and serum-protein levels. A collaborative study. Lancet ii(7728):778–80.
   Google Scholar
• Meno-Tetang GM, Lowe PJ. 2005. On the prediction of the human response: a recycled mechanistic pharmacokinetic/pharmacodynamic approach. Basic Clin Pharmacol Toxicol 96:182–92.
   PubMed Web of Science ®Google Scholar
• Moreland LW, O’Dell JR. 2002. Glucocorticoids and rheumatoid arthritis: back to the future? Arthritis Rheum 46:2553–63.
   PubMed Web of Science ®Google Scholar
• Petersen KB, Jusko WJ, Rasmussen M, Schmiegelow K. 2003. Population pharmacokinetics of prednisolone in children with acute lymphoblastic leukemia. Cancer Chemother Pharmacol 51:465–73.
   PubMed Web of Science ®Google Scholar
• Rocci ML Jr, D’Ambrosio R, Johnson NF, Jusko WJ. 1982. Prednisolone binding to albumin and transcortin in the presence of cortisol. Biochem Pharmacol 31:289–92.
   PubMed Web of Science ®Google Scholar
• Rocci ML Jr, Johnson NF, Jusko WJ. 1980. Serum protein binding of prednisolone in four species. J Pharm Sci 69:977–8.
   PubMedGoogle Scholar
• Rohatagi S, Barth J, Mollmann H, Hochhaus G, Soldner A, Mollmann C, Derendorf H. 1997. Pharmacokinetics of methylprednisolone and prednisolone after single and multiple oral administration. J Clin Pharmacol 37:916–25.
   PubMed Web of Science ®Google Scholar
• Rohatagi S, Hochhaus G, Mollmann H, Barth J, Derendorf H. 1995. Pharmacokinetic interaction between endogenous cortisol and exogenous corticosteroids. Pharmazie 50:610–3.
   PubMedGoogle Scholar
• Rose JQ, Yurchak AM, Jusko WJ. 1981. Dose dependent pharmacokinetics of prednisone and prednisolone in man. J Pharmacokinet Biopharm 9:389–417.
   PubMedGoogle Scholar
• Rosman PM, Benn R, Kay M, Tito J, Wallace EZ. 1984a. Cortisol binding in uremic plasma. I. Absence of abnormal cortisol binding to cortisol binding to corticosteroid-binding globulin. Nephron 37:160–5.
   PubMedGoogle Scholar
• Rosman PM, Benn R, Kay M, Wallace EZ. 1984b. Cortisol binding in uremic plasma. II. Decreased cortisol binding to albumin. Nephron 37:229–31.
   PubMedGoogle Scholar
• Wallwork B, Coman W, Feron F, Mackay-Sim A, Cervin A. 2002. Clarithromycin and prednisolone inhibit cytokine production in chronic rhinosinusitis. Laryngoscope 112:1827–30.
   PubMed Web of Science ®Google Scholar
• Ward KW, Coon DJ, Magiera D, Bhadresa S, Struharik M, Lawrence MS. 2009. Exploration of the African green monkey as a preclinical pharmacokinetic model: oral pharmacokinetic parameters and drug–drug interactions. Xenobiotica 39:266–72.
   PubMed Web of Science ®Google Scholar
• Yamazaki M, Aoshima K, Mizutani T, Ontachi Y, Saito M, Morishita E, Asakura H, Matsuda T, Triplett DA. 1999. Prednisolone inhibits endotoxin-induced disseminated intravascular coagulation and improves mortality in rats: importance of inflammatory cytokine suppression. Blood Coagul Fibrinolysis 10:321–30.
   PubMed Web of Science ®Google Scholar